Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Transplant Cell Ther. 2021 Mar 22;27(6):507–516. doi: 10.1016/j.jtct.2021.03.015

Table 5.

Summary of Multivariate Analysis of Study Endpoints in All Cohorts

Endpoint BM (Fresh = 456, Cryo = 154) Related PBSC (Fresh = 3030, Cryo = 1051) Unrelated PBSC (Fresh = 2028, Cryo = 678)
HR CI P E-value HR CI P E-value HR CI P E-value
Neutrophil recovery (day 28)* 0.87 0.73–1.03 .109 1.44 1.06 0.99–1.14 .104 1.25 0.77 0.71–0.84 <.001 1.69
Platelet recovery (day 100) 0.81 0.66–0.98 .028 1.58 0.73 0.68–0.78 <.001 1.79 0.61 0.56–0.66 <.001 2.16
Treatment-related mortality 1.28 0.84–1.94 .25 1.66 1.22 1.04–1.44 .015 1.56 1.4 1.18–1.66 <.001 1.84
Relapse/Progression§ 1.28 0.90–1.83 .164 1.66 0.96 0.84–1.10 .524 1.20 1.32 1.11–1.58 .002 1.72
Relapse/PFSǁ 1.25 0.95–1.65 .107 1.61 1.07 0.97–1.19 .168 1.27 1.36 1.20–1.55 <.001 1.78
OSǀ 1.34 1.00–1.80 .052 1.75 1.12 1.00–1.25 .045 1.38 1.38 1.22–1.58 <.001 1.81
aGVHD (day 100)
 Grade II-IV# 1.09 0.73–1.65 .668 1.32 1.27 1.09–1.48 .002 1.64 0.96 0.81–1.15 .683 1.2
 Grade III-IV** 1.44 0.80–2.57 .222 1.89 1.48 1.19–1.84 <.001 1.95 1.12 0.87–1.44 .381 1.38
*

Additional covariates adjusted for in multivariate analysis for neutrophil engraftment: BM: recipient age, donor age, donor type/matching, and GVHD prophylaxis; related PBSC: ATC/Campath use. conditioning regimen intensity, disease, donor-recipient CMV status, GVHD prophylaxis, KPS, use of TBI.

Additional covariates adjusted for in multivariate analysis for platelet engraftment: BM: donor type/matching, KPS; related PBSC: recipient age, disease, GVHD prophylaxis, HCT-CI, KPS, use of TBI; unrelated PBSC: recipient age, disease, donor-recipient CMV status, DRI, GVHD prophylaxis, HCT-CI, interval from diagnosis to HCT. KPS, year of HCT.

Additional covariates adjusted for in multivariate analysis for treatment-related mortality: BM: recipient age, donor type/matching, ethnicity; related PBSC: recipient age, disease, donor-recipient CMV status, DRI.ethnicity, GVHD prophylaxis, HCT-CI; unrelated PBSC: recipient age, conditioning regimen intensity, donor age, donor type/matching, donor-recipient CMV status, GVHD prophylaxis, HCT-CI, interval from diagnosis to HCT, KPS.

§

Additional covariates adjusted for in multivariate analysis for relapse/progression: BM: DRI, TBI use; related PBSC: disease, donor-recipient CMV status, DRI, HCT-CI, interval from diagnosis to HCT, year of HCT; unrelated PBSC: disease, ORI.interval from diagnosis o HCT, year of HCT.

ǁ

Additional covariates adjusted for in multivariate analysis for relapse/PFS: BM: recipient age, DRI, ethnicity; related PBSC: recipient age, disease, DRI, donor-recipient sex matching, ethnicity, HCT-CI, interval from diagnosis to HCT, KPS, year of HCT; unrelated PBSC: recipient age, conditioning regimen intensity, donor age, disease, donor type/matching, donor-recipient CMV status, DRI, GVHD prophylaxis, HCT-CI, interval from diagnosis to HCT, KPS.

ǀ

Additional covariates adjusted for in multivariate analysis for OS: BM: recipient age, DRI, ethnicity; related PBSC: recipient age, DRI, ethnicity, GVHD prophylaxis. HCT-CI, interval from diagnosis to HCT, KPS; unrelated PBSC: recipient age, conditioning regimen intensity, donor age, donor type/matching, donor-recipient CMV status, DRI, GVHD prophylaxis, HCT-CI, interval from diagnosis to HCT, KPS.

#

Additional covariates adjusted for in multivariate analysis for aGVHD grade II-IV: BM: donor type/matching, disease. GVHD prophylaxis, ATG/Campath use; related PBSC: race, disease, GVHD prophylaxis, conditioning regimen intensity. ATG/Campath use; unrelated PBSC: disease, conditioning regimen intensity, donor age, ATG/Campath use.

**

Additional covariates adjusted for in multivariate analysis for aGVHD grade III-IV: BM: donor type/matching; related PBSC: disease, GVHD prophylaxis; unrelated PBSC: sex, conditioning regimen intensity, donor type/matching, donor age, donor-recipient CMV status, ATG/Campath use.